Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.

Authors

Paul E. Goss

Massachusetts General Hospital Cancer Center, Boston, MA

Paul E. Goss , Carlos H. Barrios , Arlene Chan , Dianne M. Finkelstein , Hiroji Iwata , Miguel Martin , Ada Braun , Beiying Ding , Tapan Maniar , Robert E. Coleman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT).

First Author: R. C. Coombes

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).

First Author: Phillip M. Rappold

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.

First Author: Hope S. Rugo

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

First Author: Fatima Cardoso